Cognizant's AI and industry expertise,
combined with the NVIDIA BioNeMo generative AI platform, create a
strong foundation to improve outcomes in the healthcare and life
sciences sectors
TEANECK, N.J., March 19, 2024 /PRNewswire/ -- Cognizant (NASDAQ:
CTSH) is advancing the application of generative AI (gen AI)
technology with the NVIDIA BioNeMo platform to solve complex
challenges of drug discovery in the life sciences industry, such as
improving productivity in the development process and increasing
the speed at which new, life-saving treatments can be brought to
market.
Traditional drug discovery methodologies are process intensive
and require the analysis of vast repositories of scientific
literature and clinical data in order to reveal relevant insights.
Moreover, traditional methods are burdened with high costs and long
development lifecycles with a high rate of failure. By leveraging
gen AI technologies, clinical researchers can rapidly sift through
extensive datasets, more accurately predict interactions between
drug compounds and create new, viable drug development
pathways.
"More than any other technological breakthrough in recent
decades, generative AI has the potential to revolutionize the way
new drugs are researched, developed and brought to market, making
the creation of lifesaving discoveries faster, smarter and more
accessible to all," said Anna
Elango, EVP, Cognizant's Core Technologies & Insights.
"By collaborating with NVIDIA, Cognizant can open the path to
realizing this vision safely, responsibly and cost-effectively for
our life sciences clients."
By leveraging its deep life sciences and AI domain expertise and
NVIDIA's pretrained, industry-specific generative AI models offered
as part of BioNeMo, Cognizant aims to give clients access to a
suite of model-making services, including pretrained models,
cutting-edge frameworks, and APIs, that offers clients the quickest
path to train and customize enterprise models using their
proprietary data. The offering is intended to enable this with
reduced manual intervention for data analysis, and without the need
to write elaborate code and build or maintain infrastructure.
"Generative AI will drive the next wave of enterprise
productivity gains across industries, enabled by the NVIDIA AI
Enterprise software platform," said Alvin
DaCosta, VP, Global Consulting Partner Organization, NVIDIA.
"Using NVIDIA BioNeMo, Cognizant will help provide its life
sciences clients with advanced, secure and reliable AI services to
drive improved outcomes with custom drug discovery
applications."
Cognizant collaborates with leading global firms in
pharmaceuticals, biotech and medical devices, covering the entire
life sciences value chain from R&D to digital health. This work
contributes to the industry's ability to enhance science, improve
patient outcomes, and increase business value, by enabling a
patient-centric approach and better interactions with healthcare
professionals. Cognizant's life sciences offerings support more
than 120 global manufacturing lines and more than 18 million
patients with medical device company products.
Cognizant intends to pursue additional applications by
collaborating with NVIDIA in areas such as manufacturing and
automotive engineering, where gen AI has the potential to enhance
productivity, optimize costs and bring innovation to market more
quickly. Cognizant intends to establish an NVIDIA AI Center of
Excellence this year to further innovate with NVIDIA technologies,
including the NVIDIA Metropolis, NVIDIA Omniverse and NVIDIA
AI Enterprise platforms, for the benefit of clients across
industries around the world.
About Cognizant
Cognizant (Nasdaq: CTSH) engineers
modern businesses. We help our clients modernize technology,
reimagine processes and transform experiences so they can stay
ahead in our fast-changing world. Together, we're improving
everyday life. See how at www.cognizant.com or
@cognizant.
For more
information, contact:
|
|
|
|
|
|
U.S.
Name Ben
Gorelick
Email
benjamin.gorelick@cognizant.com
|
|
Europe /
APAC
Name Christina
Schneider
Email
christina.schneider@cognizant.com
|
|
India
Name Rashmi
Vasisht
Email
rashmi.vasisht@cognizant.com
|
Logo -
https://mma.prnewswire.com/media/1794711/Cognizant_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/cognizant-to-apply-generative-ai-to-enhance-drug-discovery-for-pharmaceutical-clients-with-nvidia-bionemo-302092233.html